Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EPS (Weighted Average and Diluted) (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed EPS (Weighted Average and Diluted) for 10 consecutive years, with $0.2 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 20.0% to $0.2 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.82 through Dec 2025, down 33.33% year-over-year, with the annual reading at $0.82 for FY2025, 33.33% down from the prior year.
  • EPS (Weighted Average and Diluted) hit $0.2 in Q4 2025 for Corcept Therapeutics, up from $0.16 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.41 in Q3 2024 to a low of $0.14 in Q4 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged $0.24 across 5 years, with a median of $0.24 in 2021.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 100.0% in 2023 and later crashed 60.98% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.26 in 2021, then crashed by 46.15% to $0.14 in 2022, then surged by 100.0% to $0.28 in 2023, then decreased by 10.71% to $0.25 in 2024, then decreased by 20.0% to $0.2 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CORT at $0.2 in Q4 2025, $0.16 in Q3 2025, and $0.29 in Q2 2025.